Westwind Capital Grows Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Westwind Capital grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,662 shares of the company’s stock after acquiring an additional 1,211 shares during the period. IDEXX Laboratories comprises approximately 4.0% of Westwind Capital’s holdings, making the stock its 11th biggest position. Westwind Capital owned 0.05% of IDEXX Laboratories worth $18,465,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. FSA Wealth Management LLC acquired a new position in IDEXX Laboratories in the third quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC grew its position in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $36,000. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $37,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock traded down $2.99 during mid-day trading on Tuesday, hitting $426.17. The company’s stock had a trading volume of 342,438 shares, compared to its average volume of 412,638. The stock has a market capitalization of $34.90 billion, a P/E ratio of 41.10, a P/E/G ratio of 3.94 and a beta of 1.36. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The stock’s fifty day moving average price is $424.02 and its two-hundred day moving average price is $461.79. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same period in the previous year, the firm posted $2.53 EPS. The company’s quarterly revenue was up 6.6% on a year-over-year basis. Research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on IDXX. Piper Sandler reiterated a “neutral” rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $539.63.

Insiders Place Their Bets

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.